| 000 | 01719 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515155404.0 | ||
| 264 | 0 | _c20090508 | |
| 008 | 200905s 0 0 eng d | ||
| 022 | _a1399-3003 | ||
| 024 | 7 |
_a10.1183/09031936.00162307 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRuppert, A-M | |
| 245 | 0 | 0 |
_aEGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. _h[electronic resource] |
| 260 |
_bThe European respiratory journal _cFeb 2009 |
||
| 300 |
_a436-40 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xpathology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCentral Nervous System Neoplasms _xsecondary |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver Neoplasms _xsecondary |
| 650 | 0 | 4 |
_aLung Neoplasms _xpathology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBeau-Faller, M | |
| 700 | 1 | _aNeuville, A | |
| 700 | 1 | _aGuerin, E | |
| 700 | 1 | _aVoegeli, A-C | |
| 700 | 1 | _aMennecier, B | |
| 700 | 1 | _aLegrain, M | |
| 700 | 1 | _aMolard, A | |
| 700 | 1 | _aJeung, M-Y | |
| 700 | 1 | _aGaub, M-P | |
| 700 | 1 | _aOudet, P | |
| 700 | 1 | _aQuoix, E | |
| 773 | 0 |
_tThe European respiratory journal _gvol. 33 _gno. 2 _gp. 436-40 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1183/09031936.00162307 _zAvailable from publisher's website |
| 999 |
_c18627352 _d18627352 |
||